We assessed the influence of human leukocyte antigen (HLA) alleles HLA-Bw4 and HLA-Bw6 on CD4 T cell recovery after starting successful combination antiretroviral therapy in 265 individuals. The median gains in the CD4 T cell count after 4 years were 258 cells/mL for HLA-Bw4 homozygotes, 321 cells/mL for HLA-Bw4/Bw6 heterozygotes, and 363 cells/mL for HLA-Bw6 homozygotes ( , compared with HLA-P p .01 Bw4 homozygotes). HLA-Bw4 homozygosity appears to predict an impaired CD4 T cell recovery after initiation of combination antiretroviral therapy.
Human leukocyte antigen (HLA) allelic variation influences the course of HIV infection by shaping adaptive and innate immune responses [1] . HLA genetic variation is most intense in regions involved in antigen-derived peptide binding. However, HLA-B molecules can also be categorized into 2 mutually exclusive HLA-Bw4 and HLA-Bw6 variants defined by amino acid sequence variation at residues 77-83 of the HLA a-1 domain [2] . The HLA-Bw4 variant, defined primarily by the presence at residue 80 of either isoleucine ("80I") or threonine ("80T"), ligates to killer cell Ig-like receptors (KIR) expressed on natural killer cells and selected T cell subsets, whereas the HLA-Bw6 variant ("80N") has no known ligands.
HLA-Bw4 homozygosity is associated with control of the HIV load, protection from AIDS [3] , and decreased risk of HIV transmission [4] . The interaction between HLA-Bw4 80I and KIR3DS1 confers protection against progression to AIDS and opportunistic infections [5, 6] . The influence of HLA-Bw4 and HLA-Bw6 alleles on recovery of the CD4 T cell count after commencement of combination antiretroviral therapy (cART) is unknown. The aim of this study was to investigate the impact of HLA-Bw4 and HLA-Bw6 alleles on CD4 T cell recovery after commencement of successful cART, with incorporation of known or potential predictors of response to cART as covariates.
Methods. Our study included antiretroviral-naive, HIVinfected individuals from the Swiss HIV Cohort Study and the Western Australian HIV Cohort Study (SHCS and WAHIV, respectively). All participants provided informed consent, including consent for genetic testing. The primary analysis was restricted to white men who had received successful, uninterrupted cART, to eliminate the potentially confounding effects of ethnicity, sex, and treatment interruptions. Thereafter, the influence of HLA-Bw4 and HLA-Bw6 alleles on CD4 T cell recovery was also assessed in an expanded population that included women and nonwhite participants. Successful cART was defined as treatment that yielded an HIV RNA level !400 copies/mL (i.e., the lower limit of assay detection during most of the study period) within 6 months and with which a suppressed HIV load was maintained throughout the study. Follow-up was censored at the point of the first virologic failure (HIV RNA level, у400 copies/mL) or if cART was stopped for 11 month. Sequenced-based, high-resolution HLA typing was performed for all individuals, and HLA-Bw4 and HLA-Bw6 carriage was determined on the basis of sequence variation at residues 77-83.
Increases in the CD4 T cell count after commencement of cART were estimated by flexible piece-wise linear profiles using mixed-effects regression, with use of S-Plus software, version 7.0 (Insightful Corp). In these analyses, the individual-specific and population-average time trends in increases in the CD4 T cell count are modeled (on the square-root scale) by continuous, piece-wise linear functions, with change points at every 12 months. CD4 T cell counts at the time of cART initiation (i.e., the baseline CD4 T cell count) influence increases in the CD4 T cell count after commencement of cART [7] ; therefore, our models allowed the slopes of the trend-line segments to depend on baseline CD4 T cell counts in addition to other covariate information (CCR5D32 carriage, age, and cART regimen). For comparisons, estimated changes in the CD4 T cell count from baseline were standardized to the median baseline CD4 T cell count (i.e., 250 cells/mL).
Results. One hundred seventy-eight participants in SHCS and 87 participants in WAHIV were included in the study. The distribution of HLA-Bw4 homozygotes (Bw4/Bw4), heterozygotes (Bw4/Bw6), and HLA-Bw6 homozygotes (Bw6/Bw6) was similar among study participants (16%, 48%, and 36%, respectively) and among 1551 healthy individuals from the Western Australian Bone Marrow Registry (13%, 46%, and 40%, respectively;
, by the x 2 test) and did not differ signifi-P p .3 cantly between SHCS and WAHIV participants.
The HLA-Bw4 homozygote, HLA-Bw4/Bw6 heterozygote, and HLA-Bw6 homozygote groups did not differ significantly with regard to the median CD4 T cell count before cART initiation (248, 240, and 273 cells/mL, respectively;
, by P p .5 analysis of variance). The median HIV RNA levels at baseline were similar for the HLA-Bw4 homozygote, HLA-Bw4/Bw6 heterozygote, and HLA-Bw6 homozygote groups (4.8, 4.8, and 4.9 log 10 copies/mL, respectively). Of the 265 participants, 195 (74%) had received uninterrupted, successful cART for 12 years, and 120 (45%) had received it for 14 years (figure 1). The 3 groups did not differ with regard to the duration of follow-up ( , by analysis of variance). A median of 12 P p .8 measurements of the CD4 T cell count (interquartile range, [8] [9] [10] [11] [12] [13] [14] [15] [16] were analyzed per patient.
After 4 years of successful cART, the median increase in the CD4 T cell count in the HLA-Bw4 homozygote group was 258 cells/mL, which was smaller than the increase in the HLA-Bw6 homozygote group (363 cells/mL; ) (table 1) . The dif-P p .01 ferences between the HLA-Bw4 and HLA-Bw6 homozygote groups remained statistically significant after adjustment for age, carriage of CCR5D32, and commencement of cART that included a protease inhibitor ( ). When we excluded P p .02 individuals with the HLA alleles that are most consistently associated with protective effects (HLA-B*57 and HLA-B*27 [1, 8, 9] ) or detrimental effects (HLA-B*35P(x) and HLA-B ho- NOTE. The changes in the CD4 T cell count from baseline were standardized to the median baseline CD4 T cell count of the combined cohort (i.e., 250 cells/mL). Increases in the CD4 T cell count that differ significantly from the reference group are shown in boldface font. IQR, interquartile range. mozygosity [10] ) on untreated HIV infection, the lower increases in the CD4 T cell count for the HLA-Bw4 homozygote group persisted (it was 100 cells/mL lower than that for the HLA-Bw6 homozygote group; in unadjusted analyses). P p .03 When female patients and nonwhite patients were included ( ), the median increase in the CD4 T cell count for n p 368 the HLA-Bw4 homozygote group after 4 years of successful cART was 88 cells/mL smaller than that for the HLA-Bw6 homozygote group (unadjusted and adjusted P values were .04 and .06, respectively) and 86 cells/mL smaller than that for the HLA-Bw4/Bw6 heterozygote group (unadjusted and adjusted P values were both .04).
Carriage of the HLA-Bw4 80T variant was associated with impaired recovery of the CD4 T cell count ( , compared P p .04 with Bw6/Bw6), whereas this effect was less pronounced for carriage of the HLA-Bw4 80I variant and was not statistically significant. Because only 9 individuals had HLA-Bw4 homozygosity without carriage of HLA-Bw4 80T, we could not assess the relative importance of HLA-Bw4 homozygosity versus HLABw4 80T carriage. In comparison with all SHCS participants (i.e., including 849 patients who did not have HLA typing results but who had received uninterrupted, successful cART), the median increases in the CD4 T cell count in our sample ( ) were lower for the HLA-Bw4 homozygote group and n p 265 higher for the heterozygote group and the HLA-Bw6 homozygote group (figure 1).
There was no significant difference between the SHCS and WAHIV populations in terms of trends in the increase in the CD4 T cell count ( ) or with regard to the HLA-Bw4 P p .7 effects (
). The estimated rates of change for differential P p .6 effects of HLA-Bw4 homozygosity, compared with HLA-Bw6 homozygosity, on recovery of the CD4 T cell count were similar in the SHCS and WAHIV populations (Ϫ0.045 vs. Ϫ0.042 square root CD4 T cell counts/month). Age was the only parameter with a significantly different effect ( ) on re-P p .04 covery of the CD4 T cell count between the SHCS and WAHIV cohorts.
The unexpected association of HLA-Bw4 homozygosity with impaired recovery of the CD4 T cell count led us to assess whether the impact of HLA-Bw4 homozygosity on CD4 T cell dynamics before commencement of cART in our population differed from that in previous reports [3] . In 95 SHCS participants with known dates of HIV seroconversion, the hazard of developing AIDS or reaching a CD4 T cell count !500 cells/ mL was significantly lower in the HLA-Bw4 homozygote group (hazard ratio, 0.36;
, by Cox regression), confirming P p .005 the protective role of HLA-Bw4 homozygosity in untreated HIV infection.
Discussion. HLA-Bw4 homozygosity was associated with an impaired recovery of the CD4 T cell count after commencement of cART. This contrasts with the protective effects of HLA-Bw4 homozygosity during untreated HIV infection [3] . There was a trend towards poorer CD4 T cell recovery in patients in the HLA-Bw4/Bw6 heterozygote group. Additional studies are warranted to determine the contribution of dominant or recessive effects of HLA-Bw4/Bw6 on recovery of the CD4 T cell count. Carriage of HLA-B*57, which has been consistently associated with protective effects in untreated HIV infection [11, 12] , tended to correlate with an impaired recovery of the CD4 T cell count during cART. This is in line with recent observations that described a trend toward poorer post-cART survival [13] and an impaired CD4 T cell recovery in the initial years of cART [14] in individuals carrying HLA-B*5701.
The reasons for the differing effects of HLA-Bw4 and HLABw6 alleles before and after commencement of cART remain unclear. The slower decrease in the CD4 T cell count and the lower rate of AIDS-related events before commencement of cART could lead to a delay in cART initiation, and a longer duration of untreated HIV infection may cause a more profound and unrecognized depletion of T cell subsets [15] . In this case, the slower decrease in the CD4 T cell count in individuals with favorable genotypes before receipt of cART could lead to a slower recovery of the CD4 T cell count after receipt of cART. Because !20% of the study participants had known dates of HIV seroconversion, we could not assess whether patients in the HLA-Bw4 homozygote group had been infected for a longer period. Alternatively, the unfavorable effect of HLABw4 homozygosity could point toward immunogenetic mechanisms (e.g., interactions between natural killer cells and T cells) that may play an important role in CD4 T cell homeostasis during cART. It remains to be determined whether the genetic association shown in this study can be explained by further analysis of patients' immunogenetic characteristics. Genetic variation in HLA alleles has a profound influence on the effectiveness of cellular immune responses, on viral escape and reversion, and on the impact of escape mutations on viral fitness in untreated HIV infection [1] . However, given the dramatic impact of cART on HIV replication, we anticipate that these mechanisms are not major determinants of CD4 T cell recovery and that they do not explain the influence of host genetic factors observed in our study.
Protective genotypes in untreated HIV infection (CCR5D32 deletion and HLA-B*57) were associated with slightly lower increases in the CD4 T cell count after commencement of cART. Although these effects were not statistically significant, this observation is in line with the finding that some genotypes with favorable effects before receipt of cART may be associated with opposite effects after receipt of cART.
The lower increases in the CD4 T cell count persisted when we excluded individuals who carried the HLA alleles most consistently associated with protective or detrimental effects. Nevertheless, we cannot exclude that effects of a small number of constituent HLA alleles within the HLA-Bw4 and HLA-Bw6 groups and not broader differences between the HLA-Bw4 and HLA-Bw6 motifs per se explain the different biological effects. Because of the extreme polymorphism at the HLA-B locus and the multitude of additional important genetic determinants in HIV infection, the effects of single HLA alleles would only be evident in very large cohorts. With the exception of the effect of age, there were no significant differences between participants from the SHCS and WAHIV cohorts, suggesting that our findings are representative for similar populations.
Our findings and previous studies from the SHCS [16] suggest that a substantial minority of HIV-infected patients demonstrate slow and/or incomplete recovery of the CD4 T cell count that cannot be sufficiently predicted by the current pretreatment clinical assessment. Because of the favorable effects of HLA-Bw4 homozygosity before commencement of cART, it could be erroneously anticipated that HLA-Bw4 homozygotes recover CD4 T cells particularly well.
This study adds to the growing knowledge about host genetic factors that influence the efficacy and tolerability of cART [13, 17] . It is uncertain at this stage whether the impaired recovery of the CD4 T cell count among patients with HLA-Bw4 homozygosity is associated with diminished recovery of functional cellular immune responses or with higher morbidity after cART initiation. Additional studies are warranted to clarify whether individualizing therapy for HIV infection on the basis of the
